文献速递其他结缔组织病自身炎症与 IgG4 相关病

抗SS-A抗体状态可分层TAFRO综合征并预测利妥昔单抗疗效

Potential stratification of TAFRO syndrome by anti-SS-A antibodies status and therapeutic response to rituximab.
PubMed 文献 · RMD Open · 2026-05-21

该综述纳入212例TAFRO综合征病例,按抗SS-A抗体状态分层分析。抗SS-A抗体阳性患者中利妥昔单抗治疗应答率显著高于阴性患者(88.9% vs 16.7%,p=0.011),而托珠单抗应答不受抗体状态影响。抗SS-A抗体阳性者血清IgG水平显著更高(p=0.020)。

要点

  • 抗SS-A抗体阳性TAFRO患者对利妥昔单抗应答率显著更高。
  • 托珠单抗疗效不受抗SS-A抗体状态影响。
  • 抗SS-A抗体阳性者血清IgG水平显著高于阴性者。

核心结论

  • TAFRO综合征存在临床异质性,抗SS-A抗体状态可能是与治疗反应相关的潜在因素。

主要发现

  • 212例中27例合并自身免疫病,以干燥综合征(SjD)最常见。
  • 抗SS-A抗体阳性37例,其中12例符合SjD分类标准。
  • 利妥昔单抗在抗SS-A抗体阳性患者中应答率显著高于阴性患者(88.9% vs 16.7%,p=0.011)。
  • 托珠单抗治疗应答不受抗SS-A抗体状态影响。
  • 抗SS-A抗体阳性患者血清IgG水平显著高于阴性患者(p=0.020)。

关键数值与推荐

  • 利妥昔单抗应答率:抗SS-A抗体阳性88.9% vs 阴性16.7%,p=0.011。
  • 血清IgG水平在抗SS-A抗体阳性与阴性患者间差异显著,p=0.020。

临床怎么用

  • 对TAFRO综合征患者可检测抗SS-A抗体,抗体阳性者或可优先考虑利妥昔单抗治疗。
  • 托珠单抗的选择无需依据抗SS-A抗体状态。

局限性

  • 回顾性分析,需进一步研究确认上述发现并阐明潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Thrombocytopaenia, anasarca, fever, reticulin fibrosis, renal dysfunction and organomegaly (TAFRO) syndrome has been reported to be associated with anti-SS-A antibodies, which activate type I interferon (IFN) signalling. We propose a subclassification of TAFRO syndrome based on the anti-SS-A antibody status, with the aim of identifying effective treatment strategies. METHODS: We reviewed TAFRO syndrome cases from the PubMed/MEDLINE databases from January 1977 to October 2024. The information on concomitant autoimmune diseases, the presence of anti-SS-A antibodies, serum IgG levels, treatment courses and clinical outcomes was collected and retrospectively analysed. Patients were stratified according to anti-SS-A antibody status, and response to tocilizumab (TCZ) or rituximab (RTX) was evaluated. RESULTS: Among 212 cases, 27 had concomitant autoimmune diseases, with Sjögren's disease (SjD) being the most common. Anti-SS-A antibody positivity was observed in 37 cases, of which 12 fulfilled the classification criteria for SjD. RTX was significantly more effective in anti-SS-A antibody-positive patients than in antibody-negative patients (88.9% vs 16.7%, p=0.011), whereas therapeutic response to TCZ was not affected by anti-SS-A antibody status. Serum IgG levels were significantly higher in anti-SS-A antibody-positive patients than in antibody-negative patients (p=0.020). CONCLUSIONS: TAFRO syndrome shows clinical heterogeneity and anti-SS-A antibody status may represent one potential factor associated with treatment response. Further studies are needed to confirm these findings and clarify the underlying mechanisms.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Suzuki T, Yamada S, Toriumi K, et al. Potential stratification of TAFRO syndrome by anti-SS-A antibodies status and therapeutic response to rituximab. RMD Open. 2026. PMID: 42167888. doi:10.1136/rmdopen-2025-006547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。